File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1097/HJH.0000000000002866
- Scopus: eid_2-s2.0-85110206227
- PMID: 34188006
- WOS: WOS:000671996500027
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Relationship between angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and COVID-19 incidence or severe disease
Title | Relationship between angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and COVID-19 incidence or severe disease |
---|---|
Authors | |
Keywords | angiotensin receptor blockers angiotensinconverting enzyme inhibitors COVID-19 incidence |
Issue Date | 2021 |
Publisher | Lippincott Williams & Wilkins, Ltd. The Journal's web site is located at http://www.jhypertension.com/ |
Citation | Journal of Hypertension, 2021, v. 39 n. 8, p. 1717-1724 How to Cite? |
Abstract | Background: Angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) may be associated with higher susceptibility of COVID-19 infection and adverse outcomes. We compared ACEI/ARB use and COVID-19 positivity in a case-control design, and severity in COVID-19 positive patients.
Methods: Consecutive patients who attended Hong Kong's public hospitals or outpatient clinics between 1 January and 28 July 2020 for COVID-19 real time-PCR (RT-PCR) tests were included. Baseline demographics, past comorbidities, laboratory tests and use of different medications were compared between COVID-19 positive and negative patients. Severe endpoints for COVID-19 positive patients were 28-day mortality, need for intensive care admission or intubation.
Results: This study included 213 788 patients (COVID-19 positive: n = 2774 patients; negative: n = 211 014). In total, 162 COVID-19 positive patients (5.83%) met the severity outcome. The use of ACEI/ARB was significantly higher amongst cases than controls (n = 156/2774, 5.62 vs. n = 6708/211014, 3.17%; P < 0.0001). Significant univariate predictors of COVID-19 positivity and severe COVID-19 disease were older age, higher Charlson score, comorbidities, use of ACEI/ARB, antidiabetic, lipid-lowering, anticoagulant and antiplatelet drugs and laboratory tests (odds ratio >1, P < 0.05). The relationship between the use of ACEI/ARB and COVID-19 positivity or severe disease remained significant after multivariable adjustment. No significant differences in COVID-19 positivity or disease severity between ACEI and ARB use were observed (P > 0.05).
Conclusion: There was a significant relationship between ACEI/ARB use and COVID-19 positivity and severe disease after adjusting for significant confounders. |
Persistent Identifier | http://hdl.handle.net/10722/300684 |
ISSN | 2023 Impact Factor: 3.3 2023 SCImago Journal Rankings: 1.134 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Tse, G | - |
dc.contributor.author | Zhou, J | - |
dc.contributor.author | Lee, S | - |
dc.contributor.author | Wong, WT | - |
dc.contributor.author | Li, X | - |
dc.contributor.author | Liu, T | - |
dc.contributor.author | Cao, Z | - |
dc.contributor.author | Zeng, DD | - |
dc.contributor.author | Wai, KCA | - |
dc.contributor.author | Wong, ICK | - |
dc.contributor.author | Cheung, BMY | - |
dc.contributor.author | Zhang, Q | - |
dc.date.accessioned | 2021-06-18T14:55:31Z | - |
dc.date.available | 2021-06-18T14:55:31Z | - |
dc.date.issued | 2021 | - |
dc.identifier.citation | Journal of Hypertension, 2021, v. 39 n. 8, p. 1717-1724 | - |
dc.identifier.issn | 0263-6352 | - |
dc.identifier.uri | http://hdl.handle.net/10722/300684 | - |
dc.description.abstract | Background: Angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) may be associated with higher susceptibility of COVID-19 infection and adverse outcomes. We compared ACEI/ARB use and COVID-19 positivity in a case-control design, and severity in COVID-19 positive patients. Methods: Consecutive patients who attended Hong Kong's public hospitals or outpatient clinics between 1 January and 28 July 2020 for COVID-19 real time-PCR (RT-PCR) tests were included. Baseline demographics, past comorbidities, laboratory tests and use of different medications were compared between COVID-19 positive and negative patients. Severe endpoints for COVID-19 positive patients were 28-day mortality, need for intensive care admission or intubation. Results: This study included 213 788 patients (COVID-19 positive: n = 2774 patients; negative: n = 211 014). In total, 162 COVID-19 positive patients (5.83%) met the severity outcome. The use of ACEI/ARB was significantly higher amongst cases than controls (n = 156/2774, 5.62 vs. n = 6708/211014, 3.17%; P < 0.0001). Significant univariate predictors of COVID-19 positivity and severe COVID-19 disease were older age, higher Charlson score, comorbidities, use of ACEI/ARB, antidiabetic, lipid-lowering, anticoagulant and antiplatelet drugs and laboratory tests (odds ratio >1, P < 0.05). The relationship between the use of ACEI/ARB and COVID-19 positivity or severe disease remained significant after multivariable adjustment. No significant differences in COVID-19 positivity or disease severity between ACEI and ARB use were observed (P > 0.05). Conclusion: There was a significant relationship between ACEI/ARB use and COVID-19 positivity and severe disease after adjusting for significant confounders. | - |
dc.language | eng | - |
dc.publisher | Lippincott Williams & Wilkins, Ltd. The Journal's web site is located at http://www.jhypertension.com/ | - |
dc.relation.ispartof | Journal of Hypertension | - |
dc.subject | angiotensin receptor blockers | - |
dc.subject | angiotensinconverting enzyme inhibitors | - |
dc.subject | COVID-19 incidence | - |
dc.title | Relationship between angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and COVID-19 incidence or severe disease | - |
dc.type | Article | - |
dc.identifier.email | Wai, KCA: awai@hku.hk | - |
dc.identifier.email | Wong, ICK: wongick@hku.hk | - |
dc.identifier.email | Cheung, BMY: mycheung@hkucc.hku.hk | - |
dc.identifier.authority | Wai, KCA=rp02261 | - |
dc.identifier.authority | Wong, ICK=rp01480 | - |
dc.identifier.authority | Cheung, BMY=rp01321 | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1097/HJH.0000000000002866 | - |
dc.identifier.pmid | 34188006 | - |
dc.identifier.scopus | eid_2-s2.0-85110206227 | - |
dc.identifier.hkuros | 322829 | - |
dc.identifier.volume | 39 | - |
dc.identifier.issue | 8 | - |
dc.identifier.spage | 1717 | - |
dc.identifier.epage | 1724 | - |
dc.identifier.isi | WOS:000671996500027 | - |
dc.publisher.place | United Kingdom | - |